Registered Office: 3rd Floor, Bhagyodaya Building, 79 Nagindas Master Road, Fort, Mumbai - 400023, Maharashtra Tel/fax: 022-22703249 E-mail: ncl.research@gmail.com Website:- www.nclfin.com

13/11/2020

To,

**Department of Corporate Services BSE** Limited. PHIROZE JEEJEEBHOY TOWERS **DALAL STREET** MUMBAl-400001, Maharashtra

Respected Sir or Madam,

Scrip Code: BSE-530557;

Sub: Submission of Q-II Results along with Limited Review Report by Statutory Auditors.

Respected Sir or Madam,

With reference to the above and in compliance with Regulation 33(3) of SEBI LODR Regulations, 2015, we are enclosing herewith this letter, Un-Audited Financial Results (Standalone) for the 2<sup>nd</sup> quarter ended (Q-II) and half year ended on September 30, 2020 for the Financial Year ended on 31st March 2021 together with "Limited Review Report" by Statutory Auditors.

The meeting was commenced at 14:30 Hrs. and concluded at 15:45 Hrs.

Kindly take the same on your record & oblige.

This is for the information of Members

Thanking You

Yours Faithfully

For NCL Research & Financial Services Limited

**Goutam Bose** 

**Managing Director** 

#### NCL RESEARCH & FINANCIAL SERVICES LIMITED

Reg. Office: 79, Bhagyoddaya Building, 3rd Floor, Nagindas Master Road, Fort, Mumbai, Maharashtra-400023 CIN: L65921MH1985PLC284739; Email Id: ncl.research@gmail.com; Website: www.nclfin.com Statement of UnAudited Financial Results for the Quarter and Six Month Ended 30th September 2020

Rs. In Lakhs) **Particulars** Sr. Quarter ended Half Year ended Year Ended No. 30-Sep-20 30-Jun-20 30-Sep-19 30-Sep-20 30-Sep-19 31-Mar-20 Unaudited Unaudited Audited Income **Revenue from Operations** Interest Income 51.374 (i) 48.589 53.105 99.963 163.733 214.136 **Dividend Income** (ii) (iii) Rental Income 0.300 0.300 0.600 1.200 (iv) Fees and commission Income Net gain on fair value changes (v) (vi) Net gain on derecognition of financial instruments under amortised cost category (vii) Sale of goods 1.25 1.247 27.837 (viii) Sale of services Other Revenue from Operatiions **Total Revenue from Operations** 52.921 48.889 53.105 101.810 163.733 243.172 Other Income Other Interest (i) 1.300 **Total Other Income** 1.300 **TOTAL INCOME (3+4)** 48.889 163.733 52.921 53.105 101.810 244.472 B Expenses **Finance Costs** Fees and commission expense Net loss on fair value changes Net loss on derecognition of financial instruments under amortised cost category Impairment on financial instruments Cost of materials consumed Purchases of Stock-in-trade 0.002 0.913 118.828 0.915 118.828 118.828 Changes in Inventories of finished goods, stock-in-trade and 10.676 1.479 -9.131 12.155 -6.600 34.251 work-in-progress Employee benefit expense 18.145 12.009 14.384 30.154 27.529 51.630 Depreciation, depletion and amortisation expense Other Expenses Professional & Legal Fees, Charges and Expenses 5.550 5.800 8.372 Stock Exchange & Other Regulatory Expenses 1.328 1.328 1.335 2.656 2.729 5.511 Travelling & Conveyance Expenses 3.304 1.389 1.350 4.693 2.700 5.300 Others 7.126 4.265 2.575 11.391 8.492 18.457 TOTAL EXPENSES 40.581 21.383 134.891 61.964 159.478 242.349 C TOTAL PROFIT BEFORE EXCEPTIONAL ITEMS AND TAX 27.506 12.341 -81.786 39.847 4.255 2.124 **Exceptional items** TOTAL PROFIT BEFORE TAX D 12.341 27.506 -81.786 39.847 4.255 2.124 Tax expense Current tax 3.204 7.152 -21.265 10.356 1.106 0.561 Deferred tax 0.004 0.013 0.004 0.013 0.013 E Total tax expenses 3.208 7.152 -21.252 10.360 1.119 0.574 NET PROFIT (LOSS) FOR THE PERIOD FROM OPERATION 9.133 20.354 -60.534 29.487 3.136 1.550 Other comprehensive income net of taxes Fair value changes on instruments carried at FVTOCI Tax effect on above items G TOTAL COMPREHENSIVE INCOME FOR THE PERIOD 9.133 20.354 -60.534 29.487 1.550 Details of equity share capital Paid-up equity share capital 2,908.500 2,908.500 2,908.500 2,908.500 2,908.500 2,908.500 Face value of equity share capital 2.000 2.000 2.000 2.000 2.000 2.000 Reserves excluding revaluation reserve 3,280.07 6,216.86 3,278.627 Earnings per share Basic earnings per share from continuing operations 0.006 0.014 -0.042 0.020 0.002



-0.042

0.020

0.002

Diluted earnings per share from continuing operations

0.001

0.001

# Figures for the quarters ended 31 March 2020 as reported in these financial results, are the balancing figures between the published year to date figures up to the end of the third quarter and nine months ended of the respective period. Further also figures for the quarter ended September 30, 2020 as reported in this Financial result is balancing figure in respect of the half yearly and published figure for the first quarter ended June 30, 2020.

#### Notes:

- The standalone audited financial statements are prepared in accordance with the Indian Accounting Standards ("Ind-AS") as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended and in
- terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

  The Financial Results of NCL RESEARCH & FINANCIAL SERVICES LIMITED ('the Company') for the period ended September 30, 2020
- have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors in their meeting held on November 13, 2020 and have been subjected to Limited Review by the Statutory Auditors of the Company.

  3 As per Indian Accounting Standard (IndAS) 108 "Operating Segment", the Company's business falls within a single business segment viz.
- As per Indian Accounting Standard (IndAS) 108 "Operating Segment", the Company's business falls within a single business segment viz. "Finance & Investments" and thus Segmental Report for the Quarter is not applicable to the Company.

4 Figures for pervious quarter/year have been re-stated/re-classified wherever necessary.

5 The Company has considered the possible effects that may result from the pandemic relating to COVID 19 on the financial results of the Company. While evaluating the impact, the Company has considered possible future uncertainties in the economic conditions because of the pandemic. However, given the limited operations of the Company during the quarter ended September 30, 2020, there has been no material impact on the financial position/ results of the Company. The Company is continuously evaluating the impact of the pandemic and will undertake necessary disclosures, as may be required.

Date : 13-Nov-20 Place : Mumbai



For NCL Research & Financial Services Limited

Sd/-

Goutam Bose Managing Director

# NCL RESEARCH & FINANCIAL SERVICES LIMITED Statement of Assets & Liabilities

(RS. in Lacs)

	(RS. in Lacs)	
Particulars	As at	As at
	30 Sept 2020	31 March 2020
	Audited	Audited
I. ASSETS		
Financial Assets		
(i) Cash and Cash Equivalents	1.358	63.825
(ii) Trade Receivables	175.852	174.605
(iii) Loans	4,546.304	4,645.534
(iv) Investments	1,187.740	989.710
(v) Other Financial assets	117.700	97.700
Total Financial Assets	6,028.955	5,971.375
Non-Financial Assets		
(i) Inventories	127.384	139.539
(ii) Current Tax Assets (Net)	84.915	87.162
(iii)Property, Plant and Equipments	2.273	2.273
(iv) Other non-financial assets	5.896	1.840
Total Non-Financial Assets	220.468	230.813
Total Assets	6,249.423	6,202.188
II. EQUITY AND LIABILITIES		
Financial Liabilities		
(i) Trade & Other Payable	20.156	2.654
(ii) Other Financial Liabilities	0.464	0.222
Total Financial Liabilities	20.619	2.874
Non-Financial Liabilities		
(i) Deferred tax Liablities	0.576	0.572
(ii) Contingnet Provisions against Standrad Assets as per RBI	11.366	11.614
Total Financial Liabilities	11.942	12.186
Total Liabilities	32.561	15.063
Equity		
(i) Equity Share Capital	2,908.500	2,908.500
(ii) Other Equity	3,308.362	3,278.62
Total Equity	6,216.862	6,187.127
Total Equity and Liabilities		
	6,249.423	6,202.188



#### NCL RESEARCH & FINANCIAL SERVICES LIMITED

· Cash Flow Statement for the half year ended 30th September 2020

(RS. in Lacks)

Particulars		Sept 30, 2020	Sept 30, 2019
Cash flow from/(used in) operating activities		00,100,2020	Gopt 60, 2015
Profit before tax	1 1	39.847	4.254
Adjustment for:		00.0	4.204
Depreciation and amortization	1 1		_
Operating profit before working capital changes		39.847	4.254
Movement in working capital:			
Net Changes in Assets		88.328	-144.424
Net Changes in Liablities	1 1	17.748	105.726
Cash generated/(used) in operations		145,923	-34.444
Income tax paid	1 1	-10,360	-1.119
Cash generated/(used) in operations	(A)	135.563	-35.563
Cash flow from/(used) investing activities			
Change in investments		-198.030	-
Cash generated/(used) in investing activities	(B)	-198.030	-
Cash flow from/(used in) financing activities Adjustments			
Cash generated/(used) in financing activities	(C)	-	-
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	-62.467	-35.563
mercaes, (accordace) in cash and cash equivalents	(ATBTC)	-02.407	-33,363
Cash and cash equivalent at beginning of year		63.825	54.498
Cash and cash equivalent at end of year	L	1.358	18.936
Net increase/(decrease) as disclosed above		-62.467	-35.563



# DBS & ASSOCIATES

### **Chartered Accountants**

Independent Auditor's Review Report on interim financial Results of NCL RESEARCH & FINANCIAL SERVICES LIMITED for the quarter and half year ended 30th September, 2020 pursuant to the Regulation 33 of the SEBI [Listing Obligation and Disclosure Requirements] Regulations, 2015

To Board of Directors NCL RESEARCH & FINANCIAL SERVICES LIMITED.

1. We have reviewed the accompanying Statement of unaudited Financial Results of NCL RESEARCH & FINANCIAL SERVICES LIMITED ("the Company"), for the Quarter and half year ended on 30<sup>th</sup> September 2020 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognitions and measurement principal laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" (IND AS-34), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued there under and other accounting principal generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 Review Of Interim Financial Information performed be the Independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. Our view is limited primarily to inquire of company personnel and analytical procedure is applied to financial data and thus provides less assurance than an audit. We have not performed an audit accordingly we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention except as mentioned in para 4 that causes us to believe that the accompanying statement, prepared in accordance with recognitions and measurement principles laid down in applicable Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013, read with relevant rules issued there under and other recognized accounting practice and policies, has not disclose the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, including the manner in which it is to be disclosed or that it contains any material misstatement.

Office Add.: 202, 93 of Poonam Complex, above HDFC Bank, Shafiti Park, Mira Road East, Thane – 401 107.

Char

Mobile No.: +91-9769794999, 9167653615

# DBS & ASSOCIATES

## Chartered Accountants

4. Note on inventory of the un-audited financial statement, valuation of the quoted share named ARIHANT MULTI COMMERCIAL LIMITED (formally known as LIFELINE DRUGS & PHARMA LTD. Amounting Rs. 51.07 Lac (shown 38000 shares@134.40) are subject to the valuation by independent valuer as the shares were not traded on stock exchange since long time and the said company has not filed his latest financial to stock exchange since 2018. As per management representation and explanation, they are under process to carrying out fair valuation of these shares.

## We draw your attention to:

- A. Some of the balances of Trade Receivables, Deposits, Loans and Advances, Advance received from customers and Trade payable are subject to confirmation from the respective parties and consequential reconciliation/adjustment arising there from, if any
- B. Note to the Un-audited financial statement, valuation of the unquoted investment are subject to the valuation by independent valuer, as per management explanation they are under process to carrying out fair valuation from registered valuer, these are shown its cost.

Our conclusion is not modified in respect of these matters.

Agcountant

For DBS & Associates

Chartered Accountants Firm Reg No: 081627N

**CA Roxy Teniwal** 

Partner M No: 141538

UDIN -20141538AAAAAZ8590 Place Mumbai Dated: 13.11.2020

Office Add.: 202, 93 of Poonam Complex, above HDFC Bank, Shaiti Park, Mira Road East, Thane – 401 107.

Mobile No.: +91-9769794999, 9167653615